Report
In place of a traditional lab, point-of-care testing (POCT) devices are compact medical equipment that are used to swiftly look for illnesses or ailments. In the doctor's office, they resemble little laboratories. The device provides prompt results right away when you provide a small sample (such as a drop of blood or urine). Quick treatment decisions are made possible by POCT for physicians. When waiting too long for lab results or in an emergency, they come in helpful. They might not be as accurate, though, as large labs. POCT devices enable faster and more convenient healthcare by bringing medical testing near your location.
POCT devices deliver speedy results, allowing medical practitioners to make decisions quickly and begin therapy. This is especially important in urgent situations and in scenarios in which time is of the essence. For instance, quick tests like the cardiac troponin test can diagnose heart attacks within minutes, enabling doctors to start the right treatments right away. Also, fast HIV tests, such as the OraQuick In-Home HIV Test, offer results in 20–40 minutes, enabling prompt medical assistance. An illustration would be the blood gases, electrolytes, and cardiac markers tests available through the Abbott i-STAT System. This enables medical professionals working in emergency rooms to assess patients' illnesses and select the best course of action rapidly.
Furthermore, by shortening the time between diagnosis and treatment, quicker diagnostics made possible by POCT devices could enhance patient outcomes. This is particularly important for life-threatening situations where prompt response can save lives. For example, in cases of sepsis, prompt detection of the infectious agent through POCT might direct drug choice, increasing patient survival rates. For instance, the Cepheid GeneXpert System enables quick testing for a number of infectious disorders as COVID-19 and tuberculosis. Early pathogen detection results in more potent therapeutic approaches.
However, the ability of POCT devices to retain accuracy equivalent to central lab testing is one of their major concerns. The precision of results may occasionally be harmed by the small sample volume and straightforward procedures. For instance, due to their reduced sensitivity when compared to laboratory techniques, fast diagnostic tests for some diseases, including malaria, may result in false negative results. When compared to gold-standard PCR testing, rapid antigen tests for COVID-19 may have reduced sensitivity, which could result in false-negative results, especially in asymptomatic people.
The global Point-of-Care Testing (POCT) Devices market is mainly classified based on product type, and end-user. On the basis of product type, the market is classified into coagulation monitoring devices, blood gas & electrolyte analyzers, hematology testing kits, cardiovascular testing kits, infectious disease testing kits, pregnancy & fertility testing kits, glucose monitoring devices, and others. By end-user, the market is categorized into hospitals & clinics, ambulatory care settings, home care settings, diagnostic centers, and others.
On the basis of the application, glucose monitoring devices are expected to hold the major market share globally. The high prevalence of diabetes, routine monitoring requirements, patient empowerment and self-management, and technology advancements are the factors driving the market growth. Millions of individuals worldwide are affected by the diabetes epidemic. Blood glucose levels must be regularly monitored in order to manage diabetes and avoid complications. The prevalence of continuous monitoring is a factor in the market dominance of glucose monitoring devices for POCTs. For instance, the International Diabetes Federation (IDF) estimates that 463 million individuals (20-79 years old) worldwide have diabetes in 2019; if current trends continue, this figure would increase to 700 million by 2045. Diabetes prevalence is high and rising, which highlights the importance of glucose monitoring devices in the POCT market.
People with diabetes need to check their blood glucose levels multiple times per day, unlike certain other medical diseases that only call for infrequent monitoring. POCT glucose monitoring devices are practical and enable users to check their blood sugar levels without having to travel to a lab or medical facility. By making well-informed decisions about their food, exercise routine, and medication, people with diabetes are given the tools they need to take charge of their health. The current trend toward patient-centered care and self-management is supported by this.
These instruments, which are often used, enable users to prick their finger, apply a drop of blood to a test strip, then insert the strip into a glucometer to obtain a quick blood glucose reading. Accu-Chek, OneTouch, and FreeStyle are a few examples. Small sensors are inserted under the skin as part of CGM systems to track interstitial glucose levels continually. A monitoring device or smartphone receives the data, which provides real-time glucose readings. Dexcom, Medtronic Guardian, and Abbott FreeStyle Libre are a few examples.
The market for Point-of-Care Testing (POCT) Devices has been dominated by North America, in particular the United States. Various reasons, such as sophisticated healthcare infrastructure, advances in technology, high spending on healthcare, and an emphasis on enhancing patient outcomes, are what fuel this dominance. With its extensive network of hospitals, clinics, and other healthcare facilities, North America is proud of its well-developed healthcare infrastructure. This architecture enables the use of POCT devices and supports their integration, enabling quick and decentralized diagnostics. For instance, one of the highest rates worldwide, the United States spent over 17.7% of its GDP on healthcare in 2019.
The area is a center for medical innovation and research. The development and commercialization of cutting-edge POCT devices are being driven by numerous eminent biotechnology and medical device corporations with headquarters in North America. The GDP of North America devotes a considerable share to healthcare expenses. For instance, in 2019, the United States spent over $3.8 trillion on healthcare. In order to enhance patient care and diagnostic capacities, healthcare providers have been able to invest in cutting-edge medical technologies, such as POCT equipment, thanks to this financial commitment. The advantages of POCT devices fit well with the focus on patient-centered care and the demand for quicker and more convenient medical services. By enabling speedier decision-making at the point of treatment, these tools improve patient outcomes and experiences.
Some of the major competitors in the global Point-of-Care Testing (POCT) Devices market include Sekisui Diagnostics LLC, Nipro Corporation, bioMérieux SA, Quidel Corporation, Nova Biomedical Corporation, Sysmex Corporation, Johnson & Johnson, Becton, Dickinson and Company (BD), Danaher Corporation, Siemens Healthineers AG, F. Hoffmann-La Roche Ltd., and Abbott Laboratories.
Point-of-Care Testing (POCT) Devices is extremely competitive with aggressive market strategies of global and regional companies looking to strengthen market position through new product launches and facility expansions. The following are some recent market developments:
Ans: The Point-of-Care Testing (POCT) Devices market was valued at XX million US$ in 2024 and is projected to reach XX million US$ by 2032, at a CAGR of XX% during the forecast period
Ans: Expansion of healthcare access in remote areas and the development of novel diagnostic technologies
Ans: Increasing demand for rapid and convenient diagnostics for timely patient care are the major driving factors
Ans: North American region is expected to have the largest share of the Point-of-Care Testing (POCT) Devices market
Ans: On the basis of the application, glucose monitoring devices are expected to hold the major market share globally. The high prevalence of diabetes, routine monitoring requirements, patient empowerment and self-management, and technology advancements are the factors driving the market growth
Backed by 1 million+ hours of research experience across the industries we cover.
Domains covered
Countries covered
Committed to timely delivery
Projects delivered